C
Christine Memmott
Researcher at Vertex Pharmaceuticals
Publications - 6
Citations - 519
Christine Memmott is an academic researcher from Vertex Pharmaceuticals. The author has contributed to research in topics: Influenza A virus subtype H5N1 & Biological activity. The author has an hindex of 6, co-authored 6 publications receiving 433 citations.
Papers
More filters
Journal ArticleDOI
Novel inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the bacterium's metabolism is constrained by the intracellular environment.
Brian C. VanderVen,Ruth J. Fahey,Wonsik Lee,Yancheng Liu,Robert B. Abramovitch,Christine Memmott,Adam M. Crowe,Lindsay D. Eltis,Emanuele Perola,David D. Deininger,Tiansheng Wang,Christopher Locher,David G. Russell +12 more
TL;DR: Mycobacterium tuberculosis (Mtb) relies on a specialized set of metabolic pathways to support growth in macrophages and is subject to a unique form of metabolic constraint induced by the presence of cholesterol, which implicate cyclic-AMP (cAMP) in regulating cholesterol utilization in Mtb.
Journal ArticleDOI
Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2.
Michael P. Clark,Mark W. Ledeboer,Ioana Davies,Randal Byrn,Jones Steven,Emanuele Perola,Alice Tsai,Marc Jacobs,Nti-Addae Kwame Wiredu,Upul K. Bandarage,Michael J. Boyd,Randy S. Bethiel,John J. Court,Deng Hongbo,John P. Duffy,Warren Dorsch,Luc J. Farmer,Huai Gao,Wenxin Gu,Katrina L. Jackson,Dylan Jacobs,Kennedy Joseph M,Brian Ledford,Jianglin Liang,Francois Maltais,Murcko Mark A,Tiansheng Wang,M. Woods Wannamaker,Hamilton B. Bennett,Joshua R. Leeman,Colleen F. McNeil,William P. Taylor,Christine Memmott,Min Jiang,Rene Rijnbrand,Christopher Bral,Ursula A. Germann,Azin Nezami,Yuegang Zhang,Francesco G. Salituro,Youssef L. Bennani,Paul S. Charifson +41 more
TL;DR: Compound 2 represents a first-in-class, orally bioavailable, novel compound that offers potential for the treatment of both pandemic and seasonal influenza and has a distinct advantage over the current standard of care treatments including potency, efficacy, and extended treatment window.
Journal ArticleDOI
Characterization of Pharmacological Efficacy of VX-148, a New, Potent Immunosuppressive Inosine 5′-Monophosphate Dehydrogenase Inhibitor
Jugnu Jain,Susan J. Almquist,Angela D. Heiser,Dina Shlyakhter,Eduardo Leon,Christine Memmott,Cameron Stuver Moody,Elmar Nimmesgern,Caroline Decker +8 more
TL;DR: It is demonstrated that VX-148 is a potent and specific IMPDH inhibitor with a favorable pharmacokinetic profile and good pharmacological activity in mice, and thus support development of V X-148 as an immunosuppressive drug.
Journal ArticleDOI
Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza
Upul K. Bandarage,Michael P. Clark,Emanuele Perola,Huai Gao,Marc Jacobs,Alice Tsai,Jeffery Gillespie,Kennedy Joseph M,Francois Maltais,Mark W. Ledeboer,Ioana Davies,Wenxin Gu,Randal Byrn,Kwame Nti Addae,Hamilton B. Bennett,Joshua R. Leeman,Jones Steven,Colleen O’Brien,Christine Memmott,Youssef L. Bennani,Paul S. Charifson +20 more
TL;DR: This work explored two strategies to eliminate observed aldehyde oxidase (AO)-mediated metabolism at the 2-position of these 7-azaindole analogues and identified multiple 2-substituted 7-azerous analogues with enhanced AO stability and one such compound is presented that demonstrates a favorable oral pharmacokinetic profile in rodents.
Journal ArticleDOI
Discovery of Novel, Orally Bioavailable β-Amino Acid Azaindole Inhibitors of Influenza PB2
Luc J. Farmer,Michael P. Clark,Michael J. Boyd,Emanuele Perola,Jones Steven,Alice Tsai,Marc Jacobs,Upul K. Bandarage,Mark W. Ledeboer,Tiansheng Wang,Deng Hongbo,Brian Ledford,Wenxin Gu,John P. Duffy,Randy S. Bethiel,Shannon Dean,Randal Byrn,Joshua R. Leeman,Rene Rijnbrand,Hamilton B. Bennett,Colleen O’Brien,Christine Memmott,Nti-Addae Kwame Wiredu,Youssef L. Bennani,Paul S. Charifson +24 more
TL;DR: Compound 4 showed strong potency versus multiple influenza-A strains, including pandemic 2009 H1N1 and avian H5N1 strains and showed a strong efficacy profile in a mouse influenza model even when treatment was initiated 48 h after infection.